Title |
-
en
Extracellular signal regulated protein kinase and c-jun N-terminal kinase are involved in ml muscarinic receptor-enhanced interleukin-2 production pathway in Jurkat cells.
|
Creator |
|
Accessrights |
open access |
Subject |
-
Other
en
muscarinic receptor
-
Other
en
interleukin-2
-
Other
en
neuroimmune interaction
-
Other
en
Jurkat cell
-
MeSH
en
Blotting, Western
-
MeSH
en
Cells, Cultured
-
MeSH
en
Enzyme-Linked Immunosorbent Assay
-
MeSH
en
Humans
-
MeSH
en
Interleukin-2/biosynthesis
-
MeSH
en
JNK Mitogen-Activated Protein Kinases
-
MeSH
en
Jurkat Cells
-
MeSH
en
Luciferases/metabolism
-
MeSH
en
Mitogen-Activated Protein Kinase 1/metabolism
-
MeSH
en
Mitogen-Activated Protein Kinases/metabolism
-
MeSH
en
RNA/biosynthesis
-
MeSH
en
RNA/isolation & purification
-
MeSH
en
Receptor, Muscarinic M1
-
MeSH
en
Receptors, Muscarinic/metabolism
-
MeSH
en
Reverse Transcriptase Polymerase Chain Reaction
-
MeSH
en
Transfection
-
NDC
499
|
Description |
-
Abstract
en
We have previously shown that m1 and m2 muscarinic receptors were expressed on human peripheral blood lymphocytes (hPBL) and that pre-stimulation of these receptors enhanced phytohemagglutinin (PHA)-induced interleukin-2 (IL-2) production. Possible intracellular signal pathways of muscarinic receptors to regulate IL-2 production were examined in human T cell line Jurkat cells. Pretreatment of the cells with muscarinic receptor agonist, oxotremorine M (Oxo-M), enhanced IL-2 production induced by phorbol 12-myristate 13-acetate (PMA)/A23187, while Oxo-M by itself did not affect IL-2 production. The enhancement of IL-2 production by Oxo-M was inhibited by 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP) an ml/m3 receptor antagonist. When the cells were pretreated with AF-DX116, an m2 antagonist, the IL-2 production enhanced by Oxo-M was further stimulated. Reverse transcription-polymerase chain reaction (RT-PCR) revealed that ml and m2 muscarinic receptors exist on Jurkat cells. The stimulation of ml receptors enhanced the PMA/A23187-induced binding activity to AP-1 consensus sequences in IL-2 promoter and production of c-Fos and c-Jun protein. The stimulation of ml receptors did not modify the DNA binding of NF-kappaB, NF-AT or Oct-1. When ml receptors were stimulated, activities of mitogen-activated protein kinase (MAPK)/extracellular signal regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) were increased, while p38 MAPK was not affected. Incubation with Oxo-M induced a transient increase in [Ca2+]i, which was abolished by pretreatment with 4-DAMP. Treatment with cyclosporin A markedly decreased the PMA/A23187-induced IL-2 promoter activity. This treatment, however, did not affect the enhancement of the promoter activity induced by ml receptor stimulation. The results suggest that transcription factor AP-1 is involved in the ml receptor-mediated enhancement of IL-2 transcript in Jurkat cells, and that pathways via MAPK/ERK and JNK, but not via p38 MAPK, are involved in the ml receptor-mediated enhancement of IL-2 promoter activity.
|
Publisher |
en
The Pharmaceutical Society of Japan
|
Date |
|
Language |
|
Resource Type |
journal article |
Version Type |
VoR |
Identifier |
HDL
http://hdl.handle.net/2115/53969
|
Relation |
-
isIdenticalTo
DOI
https://doi.org/10.1248/bpb.23.1198
-
PMID
11041251
|
Journal |
-
-
en
Biological & pharmaceutical bulletin
-
Volume Number23
Issue Number10
Page Start1198
Page End1205
|
File |
|
Oaidate |
2023-07-26 |